Britain’s GSK said on Friday it would limit the use of its ovarian cancer drug Zejula in the United States as a second treatment option to keep cancer at bay in patients whose tumors carry certain mutations. The news marks a second setback for GSK’s oncology portfolio this week, after the company on Monday revealed…